Every protocol is standardized. Every person in it is not, and that mismatch shows up in retention numbers long before anyone calls it a problem. Personalization is already routine elsewhere, from the apps on our phones to the trim levels and software options on our cars, and in medicine, where no two patients are the same, a blanket approach can be both ineffective and discouraging. Using a standard approach for unique patients lowers success rates and leads to costly, inconvenient return visits, which is why clinicians are turning to planning and manufacturing technologies that can deliver patient-specific care.
Personalization in health care comes in many forms. It can be as simple as letting patients choose between in-person and virtual appointments or as complex as using genetic information to make treatment decisions. The latter can help doctors understand which of their patients are genetically predisposed to developing certain conditions. 3D technologies can be used to plan for procedures and create patient-specific implants that replace damaged or nonexistent bone. Many companies in the mass personalization space are working to improve patient outcomes by normalizing solutions that are as unique as each patient.
Many companies are making strides in the 3D printing and planning medical space. These companies work on a variety of solutions. For example, a team of researchers from ETH Zurich working with Strait Access Technologies has completed initial testing on its 3D-printed silicone heart valves. Meanwhile, Dr. Matthew Griffith from the University of Sydney has designed a 3D-printed retina made of carbon. Clinical trials of the retina could start within the coming years and help restore patients’ sight. U.S.-based Monogram Orthopedics is designing replacement knees that are as close to patients’ original anatomy as possible, making implants less painful and less likely to fail. Finally, researchers at North Carolina State University have developed a textile-based implant containing cartilage derived from a patient’s stem cells. This type of cartilage preserves joint surfaces and was successfully tested on dogs with hip problems.
From silicone to cartilage to metal, the ability to create personalized implants on-site and get them to physicians, together with improvements in telehealth and genetics, is pushing mass personalization forward. In personalized health care, the medical field is zooming in on the individual patient to improve treatment for everyone. The same shift is overdue in clinical trials, where the protocol is standardized but participation is personal.
Improving Patient Retention Strategies with Personalized Clinical Trial Technology
Clinical trials face real challenges with retention. Low retention jeopardizes data quality, delays trial timelines, and inflates costs. Personalized clinical trial technology has become a way to improve communication, participant experience, and retention rates. Retention depends on trust, communication, and participant burden. Personalized technology focuses on these areas, adapts tools to the needs of each individual, and creates a smoother, participant-focused experience.
Personalized clinical trial technology addresses participants’ individual needs. Artificial intelligence (AI) chatbots provide 24/7 support, answer questions, guide participants, and even assist with technical issues. Consistent support reduces frustration and helps participants stay on track.
Wearable health devices are another valuable tool. These devices allow continuous monitoring, provide accurate data, and reduce the need for frequent clinic visits. This convenience allows patients to maintain their normal routines and contribute to critical research. Wearable data also leads to more reliable trial outcomes for researchers.
eConsent platforms simplify the enrollment process. They incorporate multimedia resources to make complex medical information understandable, so participants know what they have signed up for. This reduces miscommunication and increases retention. Understanding at the point of consent is the cheapest retention strategy there is.
Virtual reality (VR) simulations are another important tool. VR allows participants to experience trial processes in a simulated environment and alleviates anxiety about procedures, which helps participants feel more prepared and confident.
Enhancing Communication for Stronger Engagement
Patient retention strategies are based on effective communication, yet many participants drop out because they feel disconnected, face unclear expectations, or experience insufficient follow-ups. Personalized communication tools offer tailored updates, reminders, and educational resources to make participants feel informed and valued.
Patient portals are an example of how technology improves communication. These platforms give participants access to trial schedules, upcoming visit reminders, and test results. Mobile apps allow participants to take part in ways that suit their daily routines, which strengthens their sense of involvement and improves compliance.
Interactive feedback systems are another way to hear from participants. They can share their experience so researchers can address challenges. If a participant faces difficulties with medication adherence, researchers can offer personalized solutions, improve their overall experience, and reduce dropout.
Culturally sensitive communication strategies are crucial for diverse trials. Messaging that respects cultural differences builds trust and improves participant satisfaction.
Overcoming Barriers With Solutions Built Around People
Retention barriers are usually logistical or psychological. Participants struggle with time commitments, travel requirements, or a lack of connection with the trial team. Technology can address these barriers and dramatically improve retention rates.
Telemedicine is a way to overcome geographical barriers. Video consultations allow participants to check in with their clinical teams without needing to travel, which makes trials more accessible for those in rural areas. Accessibility promotes inclusion and produces generalizable results.
The complexity of trial procedures creates another challenge. Educational tools that adapt to participants’ literacy levels demystify medical jargon and help them understand their role in the study. This clarity makes participants more likely to stay in the study.
Financial considerations also contribute to dropout rates. Trial technology integrates reimbursement platforms to compensate participants for time and expenses. This reduces financial strain and demonstrates respect for their commitment.
Personalized clinical trial technology promotes inclusivity and allows trials to represent a diverse patient population. Diverse representation is critical for trial results to be applicable across different demographic groups. Diversity strengthens trust and retention.
Practical Benefits for Stakeholders
The advantages of adopting personalized technology extend beyond participants to researchers, sponsors, and other stakeholders. Trials with higher retention rates generate higher-quality data and are less likely to face costly delays.
Technology-driven solutions also reduce operational burdens. For example, wearable devices not only provide reliable real-time data but also reduce the need for extensive site monitoring visits. This efficiency saves time and resources while ensuring trial integrity.
Another practical benefit lies in predictive analytics. Tools that analyze participation patterns can help sponsors identify those at risk of dropping out. This allows for targeted support, such as a personal call from the trial team, which can make all the difference in keeping a participant in the study.
Finally, regulatory compliance is another area where technology shines. Automated systems reduce the likelihood of human error and ensure that trials meet regulatory standards consistently. This helps avoid costly setbacks while improving trust between sponsors, regulators, and participants.
Investing in personalized technology is not just about efficiency. It is about designing trials around the people in them. A positive participant experience reduces dropouts and encourages long-term participation, benefiting everyone involved.
Retention starts before enrollment, with a person who understood what they were agreeing to. See what trialport does for sponsors and CROs or see how the pathway works.
About the author
Keith Berelowitz has spent more than twenty years watching clinical trials work on paper and struggle in real life. He has helped run studies, advises sponsors and CROs on how they engage with people, and chairs a UK research ethics committee, where consent forms and participant information sheets cross his desk every month. That vantage point led to one conclusion: most trial problems are not failures of science. They are failures of understanding at the moment a person decides.
He founded trialport, an AI native clinical trial navigation and decision-support platform, in the belief that technology earns its place in research only when it makes a study easier to understand and a decision easier to make. Understanding comes first. Decisions follow.